Abstract:Objective To systematically assess the expression and clinical relevance of Livin in gastric cancer. Methods Published studies regarding the expression of Livin in gastric cancer with different pathological parameters (age, gender, differentiation, lymph node metastasis, invasion depth, tumor diameter) were searched (no time limit on literature) from PubMed, Embase, Corchrane library, Web of science, CBM, Wanfang and CNKI. Eligible studies were selected according to the inclusion/exclusion criteria and principle of quality evaluation, and Meta-analysis was performed by RevMan 5.3 software. Results A total of 20 studies with 1802 patients were included. The results of Meta analysis showed that Livin expression levels in patients with poorly differentiation were higher than those with moderately and highly differentiation (OR=0.19, 95%CI 0.15-0.25,P < 0.05). Livin expression levels in patients with lymphnode metastasis were higher than those without lymph node metastasis (OR=3.15, 95%CI 2.28-4.36, P < 0.05). Livin expression levels in patients with serosa and serosa outside invasion were higher than those with only subserosa invasion (OR=2.72, 95%CI 1.80-4.10, P < 0.05). Livin expression levels in patients with tumor diameter ≥5 cm were higher than those with tumor diameter <5 cm (OR=1.62, 95%CI 1.16-2.28, P < 0.05). Livin expression in male and female had no significant difference (OR=1.19, 95%CI 0.95-1.49, P > 0.05). Livin expression in patients aged ≥60 years and aged <60 years had no significant difference (OR=1.32, 95%CI 1.00-1.74, P=0.05). Conclusion Livin expression in gastric cancer is obviously related to the size of tumor, differentiation, lymph node metastasis and invasion depth. Livin can be used as an indicator for evaluation of malignant degree and progression of gastric cancer.
武亚运 张志 王进 董晓强 何宋兵▲. Livin在胃癌中表达及与临床相关性的Meta分析[J]. 中国医药导报, 2017, 14(17): 73-79.
WU Yayun ZHANG Zhi WANG Jin DONG Xiaoqiang HE Songbing▲. Meta analysis of the expression and clinical relevance of Livin in gastric cancer. 中国医药导报, 2017, 14(17): 73-79.
[1] Torre LA,Bray F,Siegel RL,et al. Global cancer statistics,2012 [J]. CA,2015,65(2):87-108.
[2] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015 [J]. CA,2016,66(2):115-132.
[3] 高欣欣,王新.影响胃癌患者预后的独立危险因素研究进展[J].肿瘤预防与治疗,2016,29(2):123-127.
[4] Kasof GM,Gomes BC. Livin,a novel inhibitor of apoptosis protein family member [J]. J Biol Chem,2001,276(5):3238-3246.
[5] Ashhab Y,Alian A,Polliack A,et al. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern [J]. FEBS Lett,2001,495(1-2):56-60.
[6] Lin JH,Deng G,Huang Q,et al. KIAP,a novel member of the inhibitor of apoptosis protein family [J]. Biochem Biophys Res Commun,2000,279(3):820-831.
[7] Vucic D,Stennicke HR,Pisabarro MT,et al. ML-IAP,a novel inhibitor of apoptosis that is preferentially expressed in human melanomas [J]. Curr Biol,2000,10(21):1359-1366.
[8] El-Mesallamy HO,Hegab HM,Kamal AM. Expression of inhibitor of apoptosis protein(IAP)Livin/BIRC7 in acute leukemia in adults:correlation with prognostic factors and outcome [J]. Leuk Res,2011,35(12):1616-1622.
[9] Cheng T,Zhang JG,Cheng YH,et al. Relationship between PTEN and Livin expression and malignancy of renal cell carcinomas [J]. Asian Pac J Cancer Prev,2012,13(6):2681-2685.
[10] Ye L,Song X,Li S,et al. Livin-alpha promotes cell proliferation by regulating G1-S cell cycle transition in prostate cancer [J]. Prostate,2011,71(1):42-51.
[11] Chen L,Ren GS,Li F,et al. Expression of Livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma [J]. World J Gastroenterol,2008,14(37):5749-5754.
[12] Yagihashi A,Ohmura T,Asanuma K,et al. Detection of autoantibodies to survivin and Livin in sera from patients with breast cancer [J]. Clin Chim Acta,2005,362(1-2):125-130.
[13] Tanabe H,Yagihashi A,Tsuji N,et al. Expression of survivin mRNA and Livin mRNA in non-small-cell lung cancer [J]. Lung Cancer,2004,46(3):299-304.
[14] Yagihashi A,Asanuma K,Tsuji N,et al. Detection of anti-Livin antibody in gastrointestinal cancer patients [J]. Clin Chem,2003,49(7):1206-1208.
[15] 孟加榕,唐忠辉,温路生,等.K-ras、Livin在不同胃黏膜病变中的表达及临床意义[J].山西医科大学学报,2016, 47(8):742-746.
[16] 曹晓静,宋晓翠,杜丽艳,等.Livin、Survivin、Fas、FasL在胃癌中的表达及相关性研究[J].现代中西医结合杂志,2015,24(36):4006-4009.
[17] 洪思蔚,李立平,麦桥勋,等.Livin蛋白在胃癌中表达情况与中医证型相关性研究[J].中华中医药杂志,2015, 30(2):632-635.
[18] 王亚东,杨留才.Livin与caspase-3蛋白在胃腺癌组织中的表达及临床意义[J]. 医学综述,2014,20(17):3252-3254.
[19] 马一倩,汪莉,马宏,等.FAF1、Livin蛋白在胃癌组织中的表达及临床意义[J].山西医科大学学报,2014,45(3):173-176,247.
[20] 黄郁晶,寇有为.VEGF、Livin与胃癌侵袭和转移的关系及其相关性[J].现代肿瘤医学,2013,21(4):799-802.
[21] 汪志兵,姜宗丹,张振玉.Livin蛋白在人胃癌中的表达研究[J].山西医药杂志,2013,42(9):513-514.
[22] 马玉英,张朝霞,陈素琼.Livin和Caspase-3在胃癌组织中的表达及其与预后的关系[J].实用医学杂志,2012, 28(22):3687-3691.
[23] 刘满华,田蕾,郭连怡,等.胃癌组织中Livin与Caspase-9的表达及临床意义[J].中国老年学杂志,2011,31(18):3454-3456.
[24] 万兵,郑志强.LIVIN、PTEN在胃癌组织中的表达及其临床意义[J].中国医师进修杂志,2010,33(4):19-21.
[25] Hou YJ,Li Y,Yuan ZH,et al. Expression of inhibitor of apoptosis protein Livin in gastric cancer and adjacent non-cancerous tissue [J]. World Chin J Digestol,2010,18(12):1196-1200.
[26] 李巧香,李冬霞.Survivin和Livin蛋白表达与胃癌生物学行为的关系[J].山东医药,2010,50(45):31-32.
[27] 应荣彪,冯俊,李建军,等.凋亡抑制因子Livin在胃癌中的表达及其临床意义[J].肿瘤学杂志,2010,16(3):217-219.
[28] 王桂美,张良明.nm23-H1和Livin表达对铂类化疗晚期胃癌预后影响[J].齐鲁医学杂志,2010,25(3):210-213.
[29] Zhao Y,Deng X,Wang Q. Expression and clinical significance of apoptosis associated genes Livin and Smac/DIABLO in human gastric carcinomas [J]. Chin J Cancer,2009,28(6):593-601.
[30] 陈晓燕,韩子华.胃癌组织中Livin蛋白的表达及其与临床病理特征和预后的关系[J].中国药物与临床,2010, 10(11):1230-1232.
[31] 刘敏丽,张生军,杨玲,等.Livin在胃癌中的表达及与Caspase 3的关系[J].天津医药,2008,36(11):850-852.
[32] Ou JM,Ye B,Qiu MK,et al. Knockdown of Livin inhibits growth and invasion of gastric cancer cells through blockade of the MAPK pathway in vitro and in vivo [J]. Int J Oncol,2014,44(1):276-284.
[33] Liang YZ,Fang TY,Xu HG,et al. Expression of CD44v6 and Livin in gastric cancer tissue [J]. Chin Med J(Engl),2012,125(17):3161-3165.
[34] Chung CY,Park YL,Kim N,et al. Expression and prognostic significance of Livin in gastric cancer [J]. Oncol Rep,2013,30(5):2520-2528.
[35] Tu SP,Chan A,Lin M,et al. Livin,a novel member of inhibitor of apoptosis,is marker of poor prognosis in gastric cancer [J]. Gastroenterology,2004,1262(4):A456.
[36] Chen P,Kong LB,Wang CS,et al. Effects of Livin gene silencing by siRNA on apoptosis and proliferation of gastric cancer cells [J]. World Chin J Digestol,2009,17(13):1346-1349.
[37] 余晓萍,张艳,朱翠明.Livin的siRNA对胃癌细胞BGC823生长与功能影响的初步研究[J].中华肿瘤防治杂志,2010, 17(21):1722-1726.
[38] 杨彬,赵瑛,王丽华,等.Livin、Caspase-3蛋白在不同胃病变组织中的表达及其临床意义[J].肿瘤药学,2015,5(1):27-32.
[39] Du Y,Zhu M,Zhou X,et al. miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB [J]. Tumor Biol,2016,37(1):1261-1269.